RB1 and acute myeloid leukemia: Preclinical evaluation of AMG 925 (i.e., AM-5922, a dual FLT3/CDK4 kinase inhibitor) in acute myeloid leukemia (AML) has demonstrated that the antitumor activity of AMG 925, was correlated with the inhibition of the pharmacodynamic markers STAT5 and RB phosphorylation, and also effective in suppressing FLT3 inhibitor-resistant mutants [59].